

1 **Chikungunya Seroprevalence among Patients Presenting with Febrile illnesses in selected health**
2 **facilities in Mt. Elgon region, Kenya.**

3 Sheila Kageha¹, Joyce M. Ngoi², Toru Kubo³, Kouichi Morita³ and Matilu Mwau¹

4 Corresponding Author: Sheila Kageha

5 Mail: skageha@kemri.go.ke

6 P.O. Box 54628 Nairobi -00200, Kenya

7 Tel. +254 722-587808

8 **Authors and Institutional Affiliations**

9 ¹Kenya Medical Research Institute, Kenya

10 ²West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and
11 Applied Sciences, University of Ghana, Accra, Ghana.

12 ³Department of Virology, Institute of Tropical Medicine, Nagasaki University, Japan.

13

14 **Abstract**

15 **Background**

16 Chikungunya is an emerging epidemic-prone vector-borne disease of considerable significance globally.
17 Infection with chikungunya virus induces an acute illness characterized by fever and painful arthralgia,
18 which can evolve to chronic arthritis and rheumatism especially in elderly patients. Whereas febrile
19 illness and arthralgia are common clinical presentations amongst residents of Mt. Elgon, the role of
20 chikungunya virus as a causative agent is undocumented. This study was carried out to determine the
21 prevalence of IgA, IgM and IgG antibodies against Chikungunya Virus (CHIKV) antigens in patients
22 presenting with acute febrile illnesses in Mt. Elgon region, Kenya.

23 **Methods:** This was a cross-sectional seroprevalence study on febrile patients visiting Endebes, Andersen
24 and Kitale County Referral Hospitals. Sociodemographic data was collected whenever possible. Serum
25 samples were collected and screened using Indirect ELISA for IgG+IgM+IgA antibodies. Sera that tested

26 positive by ELISA were subjected to standard plaque reduction neutralization assays (PRNT) performed
27 on monolayer cultures of Vero E6 cells for confirmation.

28 **Results:** By ELISA, a total of 317/1359 (23.33%) sera were positive for CHIKV antibodies. Of the 317
29 positive sera, 305 (96.21%) were of sufficient quantity and were subjected to PRNT. Ultimately, 127
30 (9.3%) samples tested positive for CHIKV neutralising antibodies by PRNT.

31 **Conclusion:** These findings suggest active circulation of CHIKV in Mt. Elgon, even though it has
32 previously been considered a non-endemic region for the virus. There is need to closely monitor and
33 continuously put in place surveillance strategies to prevent probable potential outbreaks in the future.

34 **Key words:** Chikungunya virus (CHIKV), Seroprevalence survey, Kenya, Mt. Elgon

35 **Introduction**

36 Chikungunya virus (CHIKV), an alphavirus of the Togaviridae family [1-4], was originally isolated in
37 1952-53 from the serum of a febrile patient during an outbreak that occurred in the Makonde Plateau in
38 the southern region of Tanzania [5]. It has since spread, infecting millions of people globally. CHIKV
39 infection is commonly characterised by acute fever, headaches and painful arthralgia, which can evolve to
40 chronic arthritis and rheumatism especially in elderly patients[5-7]. These symptoms are often clinically
41 indistinguishable from those caused by other arboviruses such as dengue, Onyong' nyong' (ONNV) and
42 West Nile viruses (WNV). Similarities in clinical symptoms often lead to missed opportunities to detect,
43 and consequent underreporting of CHIKV infection in areas endemic to arbovirus infections [8, 9].
44 CHIKV has become a global public health threat with reported cases of neurologic involvement,
45 fulminant hepatitis, and neonatal encephalopathy[10, 11]. Neurological forms of the disease and severe
46 cases have also been reported in the Réunion island outbreak of 2005-2006 and in Italy [12-14].

47 Currently there are no licensed specific antiviral drugs or vaccines to prevent CHIKV infection.
48 Treatment is mainly supportive and entails the use of analgesic drugs in combination with non-steroidal
49 anti-inflammatory drugs for symptomatic relief [15-17]. Patients infected with CHIKV develop robust
50 innate and adaptive immune responses that help in viral clearance and protection. Neutralising anti-
51 CHIKV IgG persists for at least 21 months [18-20].

52 CHIKV circulates in a sylvatic cycle between non-human primates/mammalian reservoir hosts and *Aedes*
53 *spp.* of mosquitoes [21]. *Aedes aegypti* is responsible for CHIKV endemicity in the tropical and sub-
54 tropical regions while *Aedes albopictus* has been associated with spread in temperate regions including
55 southern Europe, the Caribbean and southern and eastern regions of the USA. The virus is transmitted to

56 human hosts via infectious bites from *Aedes spp.* of mosquitoes [22, 23]. There has been increased
57 frequency of CHIKV outbreaks in previously non-endemic regions, which has been attributed to the
58 expansion of mosquito vector species and genetic adaptation of the virus that enhances its transmissibility
59 [24-26].

60 CHIKV originally endemic in Africa is known for its wide geographic distribution. In Africa, there have
61 been reports of human infection from Angola, Democratic Republic of Congo, Mozambique, Gabon,
62 Nigeria, Southern Africa, Tanzania, Uganda, and Burundi [27-31]. Chikungunya has since spread to Asia
63 including India and in the island countries of the Indian Ocean, Europe and America. In America, the
64 virus has been identified in 45 states, and more than 2.9 million suspected and confirmed cases and 296
65 deaths have been reported [32]. In Asia, CHIKV was first isolated in Bangkok, Thailand in 1958 [29, 33].

66 The disease was formerly thought to be self-limiting until the Reunion Island outbreaks in 2005-2006 that
67 witnessed several fatalities. Brazil has also experienced fatalities resulting from Chikungunya outbreak
68 [34].

69 In Kenya, the first outbreaks of CHIKV infection were recorded in Lamu and Mombasa in 2004[35, 36].
70 Indeed, genetic analysis of the virus responsible for the Indian Ocean epidemic showed that it originated
71 in the Kenyan Coast. CHIKV vectors are commonly found in diverse habitats, and there is reason to
72 believe that CHIKV outbreaks have occurred before. Mt. Elgon region in Trans Nzoia County has
73 substantial populations of reservoir hosts, high vector infestation and favourable climatic conditions for
74 transmission of arboviruses. Furthermore, encroachment of human populations into forested areas for
75 agricultural land has led to increased exposure to sylvatic mosquitoes that vector these viruses. This study
76 aimed to determine the seroprevalence of CHIKV infection in febrile patient population presenting in
77 selected health facilities in the region.

78

79 **Materials and Methods**

80 **Study sites and specimen collection**

81 This was a cross-sectional study conducted to determine the seroprevalence of CHIKV in febrile patients
82 visiting health facilities in Mt. Elgon region. Mt. Elgon ecosystem comprises a forest reserve and a
83 national park. The surrounding areas are heavily forested. The slopes of the mountain nearby have several
84 caves, infested with bats and other rodents. The livelihoods of the population is mainly linked to

85 agricultural production. This has seen encroachment of the forest for cultivation and exploitation of forest
86 products such as fuelwood, medicinal herbs, posts and poles, grazing and hunting for wild game.

87 The study was carried out in three health facilities located in the region: Andersen Medical centre (AMC),
88 Endebes District hospital (END) and Kitale County Referral hospital (KCRH within the County. These
89 facilities serve a large part of Trans Nzoia County. With consent, venous blood samples were collected
90 from patients ≥ 5 years of age presenting with acute febrile illnesses. Structured questionnaires were used
91 to collect socio-demographic and clinical information from a subset of study participants. Ethical
92 approval for the study protocol was sought from Kenya Medical Research Institute Ethical Review
93 Committee under SSC No.1698. All samples were anonymized at collection by assigning unique codes.

94 Storage was at -20°C at the facilities. Samples were transported in dry ice for processing at KEMRI,
95 where sera were separated, aliquoted into vials and stored at -80°C .

96 **Laboratory Assays**

97 Sera were tested for IgG+IgM+IgA antibodies against CHIKV and neutralizing antibodies against
98 CHIKV for those that tested positive by ELISA. All sera were first tested for antibodies against CHIKV
99 antigens by enzyme-linked immunosorbent assay (ELISA). An in-house indirect ELISA was performed
100 according to the methods described in the Igarashi Technical Manual (2000) with some modifications.
101 Purified CHIK viruses from infected culture fluid of C6/36 cells were used as antigens. Polyethylene
102 glycol and NaCl was used to concentrate the virus antigens, which were then purified using sucrose-
103 gradient ultracentrifugation at 50000g, for 14h at 4°C (Bundo and Igarashi, 1983) [50]. The viral antigens
104 were diluted at 250ng/100 μL with phosphate buffered saline (PBS). High- protein-binding 96-well
105 microplates (Maxisorp; Nulgenunc international, Roskilde, Denmark) were coated with 250ng/100
106 μL /well viral antigen, wrapped and incubated overnight at 4°C . Blocking was done by adding 100 μL of
107 PBS, 3% FCS (PBS-F) to all the wells and then incubated for 30 min at RT. The test sera were diluted at
108 1/1000 with PBS-F and added in duplicates to the pre-coated plates and incubation done at 37°C for 1 hr.
109 Control sera (both positive and negative controls) were run on each plate. After incubation, the plate was
110 washed three times with PBS, 0.05% Tween-20. 100 μL /well of 1:5000 diluted horseradish-conjugated
111 goat anti-human IgG+M+A (American Qualex, A139PN) [37] was added to the wells and incubated at 37
112 $^{\circ}\text{C}$ for 1h followed by washing three times. A substrate solution consisting of 5mg O-Phenylenediamine
113 dihydrochloride (OPD) (Sigma Chemical, St. Louis, MO) was added and incubated for 15 min at RT in
114 the dark. 100 μL /well of 5N Sulfuric acid was then added to stop further reaction. Absorbance (OD) of

115 each well was determined using spectrophotometer at 492nm. OD specific for CHKV was calculated as
116 follows [(Mean OD of virus coated wells) – (Mean OD of PBS-F coated wells)]. A serum sample was
117 deemed positive if the mean OD difference was ≥ 1 .

118 **Virus neutralization assay**

119 CHIKV antigens obtained from bulk virus cultures and purified by sucrose density gradient
120 ultracentrifugation were used in this assay. Titres of virus stocks were determined by plaque assays in
121 Vero cells expressed as plaque-forming units (PFU) per mL. All patient sera positive by IgG+IgM+IgA
122 ELISA were subsequently subjected to PRNT (protocol adapted from Igarashi Technical Manual, 2000).
123 This assay was used to determine the presence of CHIKV specific neutralizing antibodies in the test sera.
124 The PRNTs were performed using Vero E6 cells. CHIKV prototype strain (S 27) was used for this
125 experiment. PRNT plates were prepared by seeding Vero cells at a concentration of 1×10^5 cells/ml into
126 6-well plates at a volume of 3 ml/well. The cells were cultured in Growth Medium (EMEM (Gibco), 10%
127 FCS (Gibco), L-glutamine P/S (Gibco), 0.2mM NEAA (Gibco), NaHCO₃ supplemented for 1 day at
128 37°C, 5% CO₂ until the cells had attained 80% confluence. Test serum was diluted with Maintenance
129 Medium (MM) (EMEM, 2% FCS, L-glutamine, P/S, NEAA, NaHCO₃ supplemented) into 1:10 dilutions.
130 At the same time, standard virus dilution of 1000 PFU/ml with MM was prepared. An equal volume of
131 serum dilution (100 μ L) and standard virus dilution (100 μ L) was mixed. For positive control wells, equal
132 volumes of MM and standard virus dilution were mixed. The virus-serum mixture was then incubated for
133 1 hour at 37°C. After 1h incubation of mixture, 2.5 ml of culture medium from each well of 6-well plates
134 was aspirated and 100 μ l/well of serum/virus mixture added to Vero cells in duplicate wells. The plates
135 were then incubated for 1.5 - 2 hours in the 37°C, 5% CO₂ incubator. A total of 3ml of overlay medium
136 (EMEM, 2% FCS, 1.4% Methylcellulose, P/S supplemented) was added into each well, and incubated at
137 37°C, 5% CO₂ for 2-3 days with daily observation. Harvesting involved discarding of overlay medium
138 and fixing plates by adding 1 ml of 10% formalin in PBS over the cell and incubation for 1 hour at room
139 temperature (rt) in the safety cabinet under UV light. After incubation, the plates were then washed gently
140 with tap water at least twice, absorbed on paper towel and staining solution (0.5 ml of 1% Crystal Violet
141 solution in water) added. The stain was discarded after 5-10 minutes at room temperature and plates
142 washed gently with tap water. The plates were air-dried at room temperature and plaques counted for each
143 set of duplicate wells. The percentage reduction was calculated by comparing with the positive control
144 virus well (100% plaque formation). Sera were initially tested at a dilution of 1:20 and those that reduced
145 the number of plaques by $\geq 75\%$ (PRNT₇₀) were titrated. More than 90% plaque reduction (PRNT₉₀) was

146 regarded as positive and titers were expressed as the reciprocal of serum dilutions yielding $\geq 90\%$
147 reduction in the number of plaques.

148 **Data analysis**

149 Data analyses were performed using STATA Version 14 software (Stata Corp LP, College Station, Texas,
150 United States). Chi-square test was performed for potential association. Two-sided p values were
151 reported, and statistical significance was taken as $p < 0.05$.

152 **Results**

153 A total of 1,398 samples were collected from febrile patients in the selected health facilities and screened
154 for CHIKV antibodies. Thirty-nine (39, 2.79%) patient sera were excluded from analysis for various
155 reasons including insufficient sera volume and compromised sample integrity.

156 The main inclusion criterion for this study was fever. The minimum temperature was 38°C while the
157 maximum was 40.5°C with a mean of 39.1°C . The median duration of fever was nine days.
158 Forty-three patients complained of muscle pains. Other complaints included: jaundice, body
159 pains, abdominal pains, diarrhoea and bleeding.

160 Demographic and clinical data was available for 782/1,359 (57.54%) samples: 507 (37.31%) were
161 collected from females and 275 (20.24%) from males (Table 1). The average age of the participants was
162 31.6 years (Median 28, range 5-91 years). There was no significant difference in ages between males and
163 females, (median 31.4 and 31.7 respectively, $p > 0.6$). Data on residence of patients was available for 777
164 samples. Majority of the people resided in formerly Rift Valley Province (83.71%), followed by Western
165 Province (2.1%), Eastern Uganda (11.2%) while the rest (3%) were non-residents. Of the 1,359 samples
166 processed successfully, 689 (50.70%) were from KCRH, 463 (34.07%) from AMC and 207 (15.23%)
167 from END. A total of 317 (23.34%) samples tested antibody positive by ELISA.

168 The odds of exposure were determined for gender, health facilities, age of participants and presenting
169 symptoms (Table 1). The odds of being seropositive for CHIKV were significantly lower in END and
170 KCRH when compared with AMC, in those with fever when compared to those without, those with eye
171 infection and headache when compared to those without ($p < 0.05$).

172 **Table 1: Poisson Regression Analysis for Chikungunya Virus (CHIKV) Seropositivity**
173 **among febrile patients visiting selected health facilities in Mt. Elgon Region.**

Participant characteristics	Total pop.	CHIKV +ve (n=317)		
	n (%)	OR	95% CI	p value
Gender				
Male	275 (20.24)	Ref.		
Female	507 (37.31)	0.68	0.45 - 1.04	0.08
Missing data*	577 (42.46)	0.29	0.19 - 0.43	0.00
Age Group (Years)				
0 - 5.0	12 (0.88)	2.3	0.30 - 1.81	0.43
5.1- 20	154 (11.33)	1.08	0.65 - 1.77	0.77
20.1 - 35	376 (27.67)	Ref.		
35.1- 50	128 (9.42)	1.13	0.65 - 1.95	0.67
50.1 - 100	84 (6.18)	1.14	0.83-3.66	0.14
Missing data*	605 (44.52)	0.43	0.31-0.59	0.001
Health Facility				
AMC	463 (34.07)	Ref.		
END	207 (15.23)	0.35	0.22 - 0.56	0.00
KCRH	689 (50.70)	0.72	0.55 - 0.94	0.01
Presenting symptoms				
Fever				
No	205 (15.08)	Ref		
Yes	567 (41.72)	0.48	0.32 - 0.72	0.00
Missing data*	587 (43.19)	1.58	1.10 - 2.28	0.013
Rash				
No	556 (40.91)	Ref.		
Yes	224 (16.48)	1.07	0.70 - 1.62	0.76
Missing data*	579 (42.62)	2.72	2.03 - 3.64	0.00
Eye infection				
No	617 (45.40)	Ref.		
Yes	159 (11.70)	0.53	0.30 - 0.92	0.023
Missing data*	583 (42.90)	2.35	1.79 -3.09	0.00
Jaundice				
No	659 (48.49)	Ref		
Yes	115 (8.46)	1.06	0.62 - 1.80	0.84
Missing data*	585 (43.05)	2.67	2.02 - 3.52	0.00
Headache				
No	205 (15.08)	Ref.		
Yes	568 (41.80)	0.54	0.36 - 0.82	0.00
Missing data*	586 (43.12)	1.72	1.19 - 2.50	0.00

175 *Sociodemographic characteristics and clinical data were not collected for the first 605 study
176 participants. KCRH, Kitale County Referral Hospital, AMC, Andersen Medical Center; END,
177 Endebes District Hospital.

178
179 Of the 317 samples that tested antibody positive by ELISA, 305 (96.21%) were further subjected to
180 PRNT for CHIKV-specific neutralizing antibodies. A total of 123 (40.33%) exhibited neutralizing
181 activities for CHIKV antigens. An additional four (4) samples that were borderline negative by ELISA
182 tested PRNT positive (Table 2).

Table 2: ELISA versus PRNT Results for CHIKV

ELISA Status	CHIKV PRNT		
	Neutralizing	None Neutralizing	Total
NEG	4 80.00	1 20.00	5 100.00
POS	123 41.00	177 59.00	300 100.00
Total	127 41.64	178 58.36	305 100.00

183
184 **Discussion**
185 Our study observed an overall seroprevalence of 23.34% (317) by ELISA. PRNT results were positive for
186 9.35% (127) of all samples, confirming CHIKV activity in the region. Mt. Elgon region exhibits
187 extraordinary biodiversity due to the presence of forests, rivers, high levels of humidity and vertebrate
188 reservoirs that provides potential *Aedes spp.* breeding habitats. These ecological settings provide
189 opportunities for multiplication and the spread of vector-borne viruses in the region.

190 Agriculture is the main economic activity in the region. This has seen encroachment on forest reserves for
191 cultivation and exploitation of forest products such as fuelwood, medicinal herbs, timber, grazing and
192 hunting for wild game; increasing exposure to the sylvatic mosquitoes that vector these viruses. *Aedes*
193 *spp.* responsible for CHIKV transmission have been reported in Western Kenya in previous studies [38,
194 39].

195 The high seropositivity in this study compares with findings from past studies in the area, indicating that
196 alphaviruses, though subtle, are actively circulating in the region [40]. Other studies in Cameroon, Benin,

197 Mozambique and Guinea have shown similar results, which suggest a significant and unrecognized
198 CHIKV circulation in Africa[41-44].

199 In this study, we could not ascertain with confidence whether the seropositivity observed was due to
200 present or convalescent CHIKV and/or ONNV infections. Little is known about the lifeline of circulatory
201 CHIKV specific antibodies, beyond what is generally known about the kinetics of IgG and IgM antibodies
202 with other immune correlates. However, herd immunity has been demonstrated in populations with
203 constant contact with vectors, this could explain the observed neutralization [44, 45].

204
205 Of interest, were samples that tested positive by ELISA but failed to neutralize the CHIKV antigens by
206 PRNT 178/305 (58.36%). This suggests possible IgM/IgG cross-reactivity to closely related alphaviruses
207 circulating in the region. CHIKV belongs within the Semliki Forest virus (SFV) antigenic serocomplex
208 and therefore exhibits serological cross-reactivity[45, 46]. Co-infections with more than one etiological
209 agent have been shown to complicate diagnosis, severity and management of these viruses in patients [47,
210 48]. More diverse studies to assess CHKV antibody persistence and the likelihood of cross-protection
211 against CHIKV infection due to previous alphavirus infection could provide better insights. Findings
212 from related studies have indicated multiple genotypes that could have effects on serological outcomes
213 and epidemic potential[27, 49].

214 In Kenya, especially in malaria endemic regions, malaria is frequently diagnosed as the cause of acute
215 undifferentiated febrile illnesses while other causes like arboviruses are often overlooked. This study
216 suggests that CHIKV is an important cause of fever in Mt. Elgon and should be considered as a
217 differential diagnosis in clinical practise.

218 This study had limitations such as incomplete and insufficient demographics and clinical information that
219 hampered analysis for odds of exposure among the population.

220

221 **Conclusion**

222 From this study, we conclude that CHIKV commonly infects residents of Mt. Elgon, and is under-
223 recognized as a cause of morbidity in this population. Therefore, periodic surveillance is necessary to
224 assess the viral burden in the population and devise effective public health interventions to tackle the
225 challenge. Vector control measures are also needed to curb these infections.

226

227 Author Disclosure Statement

228 The authors declare that they have no competing interests.

229 Acknowledgement

230 This study was supported by Nagasaki University of Infectious and Tropical Medicine in collaboration
231 with the Kenya Medical Research Institute. This study appreciates the Deputy Director, Centre for Virus
232 research and the technical staff for support.

233 References

- 234 1. Higashi N, Matsumoto A, Tabata K, Nagatomo Y: **Electron microscope study of development of**
235 **Chikungunya virus in green monkey kidney stable (VERO) cells.** *Virology* 1967, **33**(1):55-69.
- 236 2. Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, Strauss JH, Weaver SC: **Evolutionary**
237 **relationships and systematics of the alphaviruses.** *Journal of virology* 2001, **75**(21):10118-
238 10131.
- 239 3. Strauss JH, Strauss EG: **The alphaviruses: gene expression, replication, and evolution.**
240 *Microbiological reviews* 1994, **58**(3):491-562.
- 241 4. Lahariya C, Pradhan SK: **Emergence of chikungunya virus in Indian subcontinent after 32 years:**
242 **A review.** *Journal of vector borne diseases* 2006, **43**(4):151-160.
- 243 5. Robinson MC: **An epidemic of virus disease in Southern Province, Tanganyika Territory, in**
244 **1952-53. I. Clinical features.** *Transactions of the Royal Society of Tropical Medicine and Hygiene*
245 1955, **49**(1):28-32.
- 246 6. Miner JJ, Aw-Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST, Kim AHJ, Diamond MS, Lenschow
247 DJ, Yokoyama WM: **Chikungunya viral arthritis in the United States: a mimic of seronegative**
248 **rheumatoid arthritis.** *Arthritis & rheumatology (Hoboken, NJ)* 2015, **67**(5):1214-1220.
- 249 7. Weaver SC: **Arrival of chikungunya virus in the new world: prospects for spread and impact on**
250 **public health.** *PLoS neglected tropical diseases* 2014, **8**(6):e2921.
- 251 8. Carey DE: **Chikungunya and dengue: a case of mistaken identity?** *Journal of the history of*
252 *medicine and allied sciences* 1971, **26**(3):243-262.
- 253 9. Seneviratne SL, Perera J: **Fever epidemic moves into Sri Lanka.** *BMJ (Clinical research ed)* 2006,
254 **333**(7580):1220-1221.
- 255 10. Rampal, Sharda M, Meena H: **Neurological complications in Chikungunya fever.** *The Journal of*
256 *the Association of Physicians of India* 2007, **55**:765-769.
- 257 11. Wielanek AC, Monredon JD, Amrani ME, Roger JC, Serveaux JP: **Guillain-Barré syndrome**
258 **complicating a Chikungunya virus infection.** *Neurology* 2007, **69**(22):2105-2107.
- 259 12. Tournebize P, Charlin C, Lagrange M: **[Neurological manifestations in Chikungunya: about 23**
260 **cases collected in Reunion Island].** *Revue neurologique* 2009, **165**(1):48-51.
- 261 13. Lemant J, Boisson V, Winer A, Thibault L, André H, Tixier F, Lemerrier M, Antok E, Cresta MP,
262 Grivard P *et al*: **Serious acute chikungunya virus infection requiring intensive care during the**
263 **Reunion Island outbreak in 2005-2006.** *Critical care medicine* 2008, **36**(9):2536-2541.
- 264 14. Elsinga J, Gerstenbluth I, van der Ploeg S, Halabi Y, Lourents NT, Burgerhof JG, van der Veen HT,
265 Bailey A, Grobusch MP, Tami A: **Long-term Chikungunya Sequelae in Curaçao: Burden,**
266 **Determinants, and a Novel Classification Tool.** *The Journal of infectious diseases* 2017,
267 **216**(5):573-581.

- 268 15. Brighton SW: **Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open**
269 **pilot study.** *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde* 1984,
270 **66(6):217-218.**
- 271 16. Staikowsky F, Le Roux K, Schuffenecker I, Laurent P, Grivard P, Develay A, Michault A:
272 **Retrospective survey of Chikungunya disease in Reunion Island hospital staff.** *Epidemiol Infect*
273 2008, **136(2):196-206.**
- 274 17. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R:
275 **On chikungunya acute infection and chloroquine treatment.** *Vector Borne Zoonotic Dis* 2008,
276 **8(6):837-839.**
- 277 18. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Rénia L *et*
278 *al*: **Longitudinal analysis of the human antibody response to Chikungunya virus infection:**
279 **implications for serodiagnosis and vaccine development.** *Journal of virology* 2012,
280 **86(23):13005-13015.**
- 281 19. Seymour RL, Adams AP, Leal G, Alcorn MD, Weaver SC: **A Rodent Model of Chikungunya Virus**
282 **Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation.** *PLoS*
283 *neglected tropical diseases* 2015, **9(6):e0003800.**
- 284 20. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle
285 KM, Fong RH *et al*: **Isolation and Characterization of Broad and Ultrapotent Human**
286 **Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.** *Cell host &*
287 *microbe* 2015, **18(1):86-95.**
- 288 21. Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M: **Chikungunya, an epidemic arbovirosis.** *The*
289 *Lancet Infectious diseases* 2007, **7(5):319-327.**
- 290 22. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D: **Vectors of Chikungunya virus in Senegal:**
291 **current data and transmission cycles.** *The American journal of tropical medicine and hygiene*
292 1999, **60(2):281-286.**
- 293 23. Arias-Goeta C, Mousson L, Rougeon F, Failloux AB: **Dissemination and transmission of the E1-**
294 **226V variant of chikungunya virus in Aedes albopictus are controlled at the midgut barrier**
295 **level.** *PloS one* 2013, **8(2):e57548.**
- 296 24. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: **A single mutation in chikungunya virus**
297 **affects vector specificity and epidemic potential.** *PLoS pathogens* 2007, **3(12):e201.**
- 298 25. Horwood PF, Buchy P: **Chikungunya.** *Revue scientifique et technique (International Office of*
299 *Epizootics)* 2015, **34(2):479-489.**
- 300 26. Tsetsarkin KA, Weaver SC: **Sequential adaptive mutations enhance efficient vector switching by**
301 **Chikungunya virus and its epidemic emergence.** *PLoS pathogens* 2011, **7(12):e1002412.**
- 302 27. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A,
303 Herrero LJ *et al*: **Chikungunya virus: an update on the biology and pathogenesis of this**
304 **emerging pathogen.** *The Lancet Infectious diseases* 2017, **17(4):e107-e117.**
- 305 28. Serگون K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, Bedno S, Burke H, Dumilla AM,
306 Konde J *et al*: **Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,**
307 **October 2004.** *The American journal of tropical medicine and hygiene* 2008, **78(2):333-337.**
- 308 29. Bhatia R, Narain JP: **Re-emerging chikungunya fever: some lessons from Asia.** *Tropical medicine*
309 *& international health : TM & IH* 2009, **14(8):940-946.**
- 310 30. Pastorino B, Muyembe-Tamfum JJ, Bessaud M, Tock F, Tolou H, Durand JP, Peyrefitte CN:
311 **Epidemic resurgence of Chikungunya virus in democratic Republic of the Congo: identification**
312 **of a new central African strain.** *Journal of medical virology* 2004, **74(2):277-282.**
- 313 31. D'Ortenzio E, Grandadam M, Balleydier E, Jaffar-Bandjee MC, Michault A, Brottet E, Baviile M,
314 Filleul L: **A226V strains of Chikungunya virus, Réunion Island, 2010.** *Emerging infectious*
315 *diseases* 2011, **17(2):309-311.**

- 316 32. Centers for Disease Control and Prevention tUSoACvgdAfhwcgcihLu.
- 317 33. Arankalle VA, Shrivastava S, Cherian S, Gunjekar RS, Walimbe AM, Jadhav SM, Sudeep AB, Mishra
318 AC: **Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to**
319 **the 2005-2006 explosive epidemic.** *The Journal of general virology* 2007, **88**(Pt 7):1967-1976.
- 320 34. Brito CAA: **Alert: Severe cases and deaths associated with Chikungunya in Brazil.** *Revista da*
321 *Sociedade Brasileira de Medicina Tropical* 2017, **50**(5):585-589.
- 322 35. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CHL, Sang R, Sergon K,
323 Breiman R, Powers AM: **Tracking epidemic Chikungunya virus into the Indian Ocean from East**
324 **Africa.** *The Journal of general virology* 2008, **89**(Pt 11):2754-2760.
- 325 36. Sang RC, Ahmed O, Faye O, Kelly CL, Yahaya AA, Mmadi I, Toilibou A, Sergon K, Brown J, Agata N
326 *et al*: **Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros,**
327 **2005.** *The American journal of tropical medicine and hygiene* 2008, **78**(1):77-82.
- 328 37. Peyrefitte CN, Rousset D, Pastorino BA, Pouillot R, Bessaud M, Tock F, Mansaray H, Merle OL,
329 Pascual AM, Paupy C *et al*: **Chikungunya virus, Cameroon, 2006.** *Emerg Infect Dis* 2007,
330 **13**(5):768-771.
- 331 38. Eastwood G, Sang RC, Guerbois M, Taracha ELN, Weaver SC: **Enzootic Circulation of**
332 **Chikungunya Virus in East Africa: Serological Evidence in Non-human Kenyan Primates.** *The*
333 *American journal of tropical medicine and hygiene* 2017, **97**(5):1399-1404.
- 334 39. Ajamma YU, Onchuru TO, Ouso DO, Omondi D, Masiga DK, Villinger J: **Vertical transmission of**
335 **naturally occurring Bunyamwera and insect-specific flavivirus infections in mosquitoes from**
336 **islands and mainland shores of Lakes Victoria and Baringo in Kenya.** 2018, **12**(11):e0006949.
- 337 40. Mease LE, Coldren RL, Musila LA, Prosser T, Ogolla F, Ofula VO, Schoepp RJ, Rossi CA, Adungo N:
338 **Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-**
339 **sectional study.** *Virology journal* 2011, **8**:371.
- 340 41. Adam A, Seidahmed OM, Weber C, Schnierle B, Schmidt-Chanasit J, Reiche S, Jassoy C: **Low**
341 **Seroprevalence Indicates Vulnerability of Eastern and Central Sudan to Infection with**
342 **Chikungunya Virus.** *Vector borne and zoonotic diseases (Larchmont, NY)* 2016, **16**(4):290-291.
- 343 42. António VS, Muianga AF, Wieseler J, Pereira SA, Monteiro VO, Mula F, Chelene I, Chongo IS,
344 Oludele JO, Kümmerer BM *et al*: **Seroepidemiology of Chikungunya Virus Among Febrile**
345 **Patients in Eight Health Facilities in Central and Northern Mozambique, 2015-2016.** *Vector*
346 *borne and zoonotic diseases (Larchmont, NY)* 2018, **18**(6):311-316.
- 347 43. Jentes ES, Robinson J, Johnson BW, Conde I, Sakouvougui Y, Iverson J, Beecher S, Bah MA,
348 Diakite F, Coulibaly M *et al*: **Acute arboviral infections in Guinea, West Africa, 2006.** *The*
349 *American journal of tropical medicine and hygiene* 2010, **83**(2):388-394.
- 350 44. Antonio VS, Amade NA, Muianga AF, Ali S, Monteiro V, Mula F, Chelene I, Oludele J:
351 **Retrospective investigation of antibodies against chikungunya virus (CHIKV) in serum from**
352 **febrile patients in Mozambique, 2009-2015: Implications for its prevention and control.** 2019,
353 **14**(3):e0213941.
- 354 45. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, Borland E, Gildengorin G,
355 Pfeil S, Teng CY *et al*: **High rates of o'nyong nyong and Chikungunya virus transmission in**
356 **coastal Kenya.** *PLoS neglected tropical diseases* 2015, **9**(2):e0003436.
- 357 46. Powers AM, Logue CH: **Changing patterns of chikungunya virus: re-emergence of a zoonotic**
358 **arbovirus.** *The Journal of general virology* 2007, **88**(Pt 9):2363-2377.
- 359 47. Yong LS, Koh KC: **A case of mixed infections in a patient presenting with acute febrile illness in**
360 **the tropics.** *Case reports in infectious diseases* 2013, **2013**:562175.
- 361 48. Makiala-Mandanda S, Ahuka-Mundeke S, Abbate JL, Pukuta-Simbu E, Nsio-Mbeta J, Berthet N,
362 Leroy EM, Becquart P, Muyembe-Tamfum JJ: **Identification of Dengue and Chikungunya Cases**

363 **Among Suspected Cases of Yellow Fever in the Democratic Republic of the Congo. *Vector***
364 ***borne and zoonotic diseases (Larchmont, NY) 2018, 18(7):364-370.***

365 49. Zeller H, Van Bortel W, Sudre B: **Chikungunya: Its History in Africa and Asia and Its Spread to**
366 **New Regions in 2013-2014. *The Journal of infectious diseases* 2016, 214(suppl 5):S436-s440.**

367

368

369

370

371